Patterns of bone density evaluation in a community population treated with aromatase inhibitors (Q34335213)

1 August 2017

title

Patterns of bone density evaluation in a community population treated with aromatase inhibitors (English)

1 reference

1 August 2017

2

A James O'Malley

1 reference

1 August 2017

6

Nancy L Keating

1 reference

1 August 2017

5

Eric P Winer

1 reference

1 August 2017

1

Jennifer A Ligibel

1 reference

1 August 2017

3

Maxine Fisher

1 reference

1 August 2017

Gregory W Daniel

4

1 reference

1 August 2017

language of work or name

English

0 references

publication date

12 July 2012

1 reference

Breast Cancer Research and Treatment

1 August 2017

published in

1 reference

1 August 2017

volume

134

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

1305-1313

1 reference

Fracture risk and bone mineral density reduction associated with proton pump inhibitors

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Clinical review: Effect of endocrine therapies on bone in breast cancer patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

NCCN Task Force Report: Bone Health in Cancer Care

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Practical guidance for the management of aromatase inhibitor-associated bone loss

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Bone density testing in older women and its association with patient age.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Quality of Non–Breast Cancer Health Maintenance Among Elderly Breast Cancer Survivors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

Development of a comorbidity index using physician claims data

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3449001

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

6 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2151-0

Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2151-0

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2151-0

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2151-0

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2151-0

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2151-0

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2151-0

Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2151-0

NCCN Task Force Report: Bone Health and Cancer Care

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22791365

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10549-012-2151-0

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference

1 August 2017

1 reference